Combination drug treatment for Richter syndrome after CLL
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of four drugs for people whose chronic lymphocytic leukemia (CLL) has transformed into a more aggressive lymphoma called Richter syndrome. The goal is to see if this combination can control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your CLL must have transformed into a specific type of aggressive lymphoma (large B-cell) that is related to your original CLL.
- Your cancer must not be in your brain or spinal cord.
- You must be able to swallow pills and attend regular clinic visits.
- You cannot have already received certain treatments: pirtobrutinib, lisaftoclax, CAR-T therapy, or a stem cell transplant.
- Your kidney, liver, and blood counts must meet minimum levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called glofitamab combined with standard chemo-immunotherapy (rituximab or obinutuzumab plus CHOP) for people with Richter syndrome, an aggressive lymphoma that arises from CLL. The goal is to see if the combination is safe and effective.
This trial tests a combination of two targeted drugs for people with Richter's transformation, an aggressive lymphoma that can develop from CLL. The goal is to see if this combination can help control the disease.
This study tests a combination of two oral drugs (nemtabrutinib and pembrolizumab) for people with Richter transformation, an aggressive lymphoma that develops from chronic lymphocytic leukemia. It may be an option if standard chemotherapy is not suitable or if prior treatment has stopped working.
This study tests whether adding a targeted drug called pirtobrutinib to the usual chemotherapy for Richter transformation can improve outcomes. It is a phase 3 trial, meaning it compares the new combination to the standard approach, and may help patients live longer or delay progression.
This trial tests a new immunotherapy drug (mosunetuzumab) combined with standard chemotherapy (CHOP) as the first treatment for Richter's syndrome, a fast-growing lymphoma that can arise from CLL. The goal is to see if this combination helps control the disease better than standard therapy.
This trial tests a new combination of two targeted drugs for people with mantle cell lymphoma that has not responded to or has returned after treatment with a BTK inhibitor. The drugs aim to block cancer cell growth and survival pathways to potentially control the disease.
Hear when a new Richter Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.